adebrelimab 
GtoPdb Ligand ID: 13085
|
Synonyms: Arelili® | Ariely® | HTI-1088 | HTI1088 | SHR-1316 | SHR1316
adebrelimab is an approved drug (China NMPA (2023))
Compound class:
Synthetic organic
Comment: Adebrelimab (SHR-1316; HTI-1088) is a chimeric humanized IgG4κ anti-PD-L1 monoclonal antibody.
|
| No information available. |
Summary of Clinical Use  |
| Adebrelimab was advanced as a clinical candidate, for the treament of advanced solid tumours [2]. First approval was granted in China on 14th March 2023. It is indicated for the treament of advanced small cell lung cancer (SCLC) |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | Phase 3 Interventional | Jiangsu HengRui Medicine Co., Ltd. | ||
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | Phase 1/Phase 2 Interventional | Jiangsu HengRui Medicine Co., Ltd. | ||
| NCT04215471 | NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma | Phase 2 Interventional | Shanghai Zhongshan Hospital | ||
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | Phase 3 Interventional | Jiangsu HengRui Medicine Co., Ltd. | 3 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License